pilsicainide has been researched along with Myocardial Ischemia in 5 studies
pilsicainide: structure given in first source
pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "No evidence of ischemic heart disease was detected." | 5.30 | Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia. ( Ito, H; Nakamura, W; Segawa, K; Tanaka, S; Yoshimoto, N, 1998) |
| "The aim of this study was to elucidate whether the electrophysiologic properties of pilsicainide, a novel class IC drug with slow kinetic properties, could be altered in the presence of acute myocardial ischemia." | 3.69 | Ischemia enhances use-dependent sodium channel blockade by pilsicainide, a class IC antiarrhythmic agent. ( Ogawa, S; Sadanaga, T, 1994) |
| "No evidence of ischemic heart disease was detected." | 1.30 | Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia. ( Ito, H; Nakamura, W; Segawa, K; Tanaka, S; Yoshimoto, N, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Omichi, C | 1 |
| Fujimoto, N | 1 |
| Kawasaki, A | 1 |
| Kasai, A | 1 |
| Niwano, S | 1 |
| Inuo, K | 1 |
| Morohoshi, Y | 1 |
| Nakayama, S | 1 |
| Yuge, M | 1 |
| Imaki, R | 1 |
| Izumi, T | 1 |
| Sadanaga, T | 1 |
| Ogawa, S | 1 |
| Liu, JX | 1 |
| Tanonaka, K | 1 |
| Ohtsuka, Y | 1 |
| Sakai, Y | 1 |
| Takeo, S | 1 |
| Nakamura, W | 1 |
| Segawa, K | 1 |
| Ito, H | 1 |
| Tanaka, S | 1 |
| Yoshimoto, N | 1 |
5 other studies available for pilsicainide and Myocardial Ischemia
| Article | Year |
|---|---|
Ischemia-induced Brugada-type ST-segment alternans and Brugada syndrome.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Brugada Syndrome; Bundle-Branch Block; Coronary Artery | 2010 |
Mexiletine protects myocardium during acute ischemia by opening sarcolemmal K-ATP channel: studies in closed-chest acute ischemia model in rabbits.
Topics: Acute Disease; Animals; Anti-Arrhythmia Agents; ATP-Binding Cassette Transporters; Disease Models, A | 2004 |
Ischemia enhances use-dependent sodium channel blockade by pilsicainide, a class IC antiarrhythmic agent.
Topics: Acute Disease; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chi-Square | 1994 |
Improvement of ischemia/reperfusion-induced contractile dysfunction of perfused hearts by class Ic antiarrhythmic agents.
Topics: Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Creatine Kinase; Flecainide; Heart; Lidocai | 1993 |
Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia.
Topics: Anti-Arrhythmia Agents; Diagnosis, Differential; Drug Therapy, Combination; Electrocardiography; Fle | 1998 |